par Ghoteimi, Rayane;Nguyen, >Van Tai;Rahimova, Rahila;Grosjean, Félix ;Cros‐Perrial, Emeline;Uttaro, Jean-Pierre;Mathé, Christophe;Chaloin, Laurent;Jordheim, Lars Petter;Peyrottes, Suzanne
Référence ChemMedChem, 14, 15, page (1431-1443)
Publication Publié, 2019-08-01
Référence ChemMedChem, 14, 15, page (1431-1443)
Publication Publié, 2019-08-01
Article révisé par les pairs
Résumé : | Abstract Derivatives of 5′‐aminoadenosine containing methyl carboxylate, methyl phosphonate, gem‐bisphosphonate, bis(methylphosphonate), and α‐carboxylmethylphosphonate or phosphonoacetate moieties were synthesized from key intermediate 5′‐aminonucleoside. These nucleotide analogues were envisaged as 5′‐mono‐ or diphosphate nucleoside mimics. All compounds were evaluated for CD73 inhibition in a cell‐based assay (MDA‐MB‐231) and toward the purified recombinant protein. Most of them failed to reach significant inhibition of AMP hydrolysis by CD73 at 100 μ m . Among the new compounds, the most interesting candidates, 5 (5′‐deoxy‐5′‐ N ‐phosphonomethyladenosine) and 7 (5′‐deoxy‐5′‐ N ‐(ethoxyphosphorylacetate)adenosine), inhibited recombinant CD73 by 36 and 46 % and cellular CD73 by 61 and 45 % at 100 μ m , respectively. Molecular modeling partially explains this lack of activity, as the initially predicted docking scores had been encouraging, especially for compound 9 . |